{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:17:16Z","timestamp":1789906636873,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alexion, AstraZeneca Rare Disease"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40801-024-00457-8","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T10:02:58Z","timestamp":1730196178000},"page":"593-601","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization"],"prefix":"10.1007","volume":"11","author":[{"given":"Richard J.","family":"Nowak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Klink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Muppidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Parthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Chloe","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandrina","family":"Balanean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajeet","family":"Gajra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-8617","authenticated-orcid":false,"suffix":"Jr","given":"James F.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ELEVATE Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"457_CR1","doi-asserted-by":"publisher","first-page":"175628641983224","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1756286419832242. https:\/\/doi.org\/10.1177\/1756286419832242.","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"457_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CND.0000000000000034","volume":"15","author":"NJ Silvestri","year":"2014","unstructured":"Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis. 2014;15(4):167\u201378. https:\/\/doi.org\/10.1097\/CND.0000000000000034.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"1","key":"457_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","volume":"1","author":"LC Wendell","year":"2011","unstructured":"Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011;1(1):16\u201322. https:\/\/doi.org\/10.1177\/1941875210382918.","journal-title":"Neurohospitalist."},{"issue":"1","key":"457_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/mus.26114","volume":"58","author":"NM Engel-Nitz","year":"2018","unstructured":"Engel-Nitz NM, Boscoe A, Wolbeck R, Johnson J, Silvestri NJ. Burden of illness in patients with treatment refractory myasthenia gravis. Muscle Nerve. 2018;58(1):99\u2013105. https:\/\/doi.org\/10.1002\/mus.26114.","journal-title":"Muscle Nerve"},{"issue":"6","key":"457_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/mus.26689","volume":"60","author":"RR Gummi","year":"2019","unstructured":"Gummi RR, Kukulka NA, Deroche CB, Govindarajan R. Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve. 2019;60(6):693\u20139. https:\/\/doi.org\/10.1002\/mus.26689.","journal-title":"Muscle Nerve"},{"issue":"5","key":"457_CR6","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/wnl.48.5.1253","volume":"48","author":"CE Thomas","year":"1997","unstructured":"Thomas CE, Mayer SA, Gungor Y, Swarup R, Webster EA, Chang I, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology. 1997;48(5):1253\u201360. https:\/\/doi.org\/10.1212\/wnl.48.5.1253.","journal-title":"Neurology"},{"key":"457_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ijcard.2019.09.054","volume":"299","author":"R Desai","year":"2020","unstructured":"Desai R, Abbas SA, Fong HK, Lodhi MU, Doshi R, Savani S, et al. Burden and impact of takotsubo syndrome in myasthenic crisis: a national inpatient perspective on the under-recognized but potentially fatal association. Int J Cardiol. 2020;299:63\u20136. https:\/\/doi.org\/10.1016\/j.ijcard.2019.09.054.","journal-title":"Int J Cardiol"},{"issue":"2","key":"457_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/CND.0b013e31822c34dd","volume":"13","author":"C Heatwole","year":"2011","unstructured":"Heatwole C, Johnson N, Holloway R, Noyes K. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. J Clin Neuromuscul Dis. 2011;13(2):85\u201394. https:\/\/doi.org\/10.1097\/CND.0b013e31822c34dd.","journal-title":"J Clin Neuromuscul Dis"},{"key":"457_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.809999","volume":"12","author":"G Phillips","year":"2021","unstructured":"Phillips G, Abreu C, Goyal A, Li Y, Whangbo A, Gelinas D, et al. Real-world healthcare resource utilization and cost burden assessment for adults with generalized myasthenia gravis in the United States. Front Neurol. 2021;12: 809999. https:\/\/doi.org\/10.3389\/fneur.2021.809999.","journal-title":"Front Neurol"},{"issue":"2","key":"457_CR10","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000207863","volume":"102","author":"AA Habib","year":"2024","unstructured":"Habib AA, Sacks N, Cool C, Durgapal S, Dennen S, Everson K, et al. Hospitalizations and mortality from myasthenia gravis: trends from 2 US national datasets. Neurology. 2024;102(2): e207863. https:\/\/doi.org\/10.1212\/wnl.0000000000207863.","journal-title":"Neurology"},{"issue":"12","key":"457_CR11","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/s1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386. https:\/\/doi.org\/10.1016\/s1474-4422(17)30369-1.","journal-title":"Lancet Neurol"},{"issue":"1","key":"457_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","volume":"60","author":"S Muppidi","year":"2019","unstructured":"Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60(1):14\u201324. https:\/\/doi.org\/10.1002\/mus.26447.","journal-title":"Muscle Nerve"},{"issue":"9","key":"457_CR13","doi-asserted-by":"publisher","first-page":"6114","DOI":"10.1007\/s00415-024-12569-w","volume":"271","author":"AA Habib","year":"2024","unstructured":"Habib AA, Klink AJ, Muppidi S, Parthan A, Sader SC, Balanean A, et al. United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use. J Neurol. 2024;271(9):6114\u201326. https:\/\/doi.org\/10.1007\/s00415-024-12569-w.","journal-title":"J Neurol"},{"issue":"1","key":"457_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000512077","volume":"84","author":"AR Abuzinadah","year":"2021","unstructured":"Abuzinadah AR, Alanazy MH, Butt NS, Barohn RJ, Dimachkie MM. Exacerbation rate in generalized myasthenia gravis and its predictors. Eur Neurol. 2021;84(1):43\u20138. https:\/\/doi.org\/10.1159\/000512077.","journal-title":"Eur Neurol"},{"key":"457_CR15","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1: EVIDoa2100066. https:\/\/doi.org\/10.1056\/EVIDoa2100066.","journal-title":"NEJM Evid."},{"issue":"9","key":"457_CR16","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1007\/s00415-024-12588-7","volume":"271","author":"C Pane","year":"2024","unstructured":"Pane C, Di Stefano V, Cuomo N, Sarnataro A, Vinciguerra C, Bevilacqua L, et al. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. J Neurol. 2024;271(9):6209\u201319. https:\/\/doi.org\/10.1007\/s00415-024-12588-7.","journal-title":"J Neurol"},{"issue":"2","key":"457_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3233\/JND-200584","volume":"8","author":"N Katyal","year":"2021","unstructured":"Katyal N, Narula N, Govindarajan R. Clinical experience with eculizumab in treatment-refractory acetylcholine receptor antibody-positive generalized myasthenia gravis. J Neuromuscul Dis. 2021;8(2):287\u201394. https:\/\/doi.org\/10.3233\/JND-200584.","journal-title":"J Neuromuscul Dis."},{"issue":"7","key":"457_CR18","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","volume":"38","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Pogoryelova O, Sejersen T, Zethraeus N, Breiner A, Lochmuller H. Economic costs of myasthenia gravis: a systematic review. Pharmacoeconomics. 2020;38(7):715\u201328. https:\/\/doi.org\/10.1007\/s40273-020-00912-8.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"457_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/13548506.2020.1807577","volume":"26","author":"C Liu","year":"2021","unstructured":"Liu C, Li T, Wang Q, Xu A, Wu B. Post-traumatic stress disorder symptoms after respiratory insufficiency in patients with myasthenia gravis. Psychol Health Med. 2021;26(2):221\u20137. https:\/\/doi.org\/10.1080\/13548506.2020.1807577.","journal-title":"Psychol Health Med"},{"issue":"2","key":"457_CR20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40120-021-00285-w","volume":"10","author":"N Law","year":"2021","unstructured":"Law N, Davio K, Blunck M, Lobban D, Seddik K. The lived experience of myasthenia gravis: a patient-led analysis. Neurol Ther. 2021;10(2):1103\u201325. https:\/\/doi.org\/10.1007\/s40120-021-00285-w.","journal-title":"Neurol Ther."},{"issue":"3","key":"457_CR21","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","volume":"94","author":"B Neumann","year":"2020","unstructured":"Neumann B, Angstwurm K, Mergenthaler P, Kohler S, Schonenberger S, Bosel J, et al. Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases. Neurology. 2020;94(3):e299\u2013313. https:\/\/doi.org\/10.1212\/WNL.0000000000008688.","journal-title":"Neurology"},{"issue":"3","key":"457_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.59566\/IJBS.2009.5209","volume":"5","author":"N Souayah","year":"2009","unstructured":"Souayah N, Nasar A, Suri MF, Kirmani JF, Ezzeddine MA, Qureshi AI. Trends in outcomes and hospitalization charges among mechanically ventilated patients with myasthenia gravis in the United States. Int J Biomed Sci. 2009;5(3):209\u201314.","journal-title":"Int J Biomed Sci"},{"issue":"6","key":"457_CR23","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1001\/archneur.1982.00510180028007","volume":"39","author":"RL Rodnitzky","year":"1982","unstructured":"Rodnitzky RL, Goeken JA. Complications of plasma exchange in neurological patients. Arch Neurol. 1982;39(6):350\u20134. https:\/\/doi.org\/10.1001\/archneur.1982.00510180028007.","journal-title":"Arch Neurol"},{"issue":"6","key":"457_CR24","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/s0272-6386(12)80135-1","volume":"23","author":"MH Mokrzycki","year":"1994","unstructured":"Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994;23(6):817\u201327. https:\/\/doi.org\/10.1016\/s0272-6386(12)80135-1.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"457_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.pharmthera.2004.04.002","volume":"102","author":"MC Dalakas","year":"2004","unstructured":"Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther. 2004;102(3):177\u201393. https:\/\/doi.org\/10.1016\/j.pharmthera.2004.04.002.","journal-title":"Pharmacol Ther"},{"key":"457_CR26","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","volume":"9","author":"Y Guo","year":"2018","unstructured":"Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299. https:\/\/doi.org\/10.3389\/fimmu.2018.01299.","journal-title":"Front Immunol"},{"issue":"8","key":"457_CR27","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","volume":"270","author":"A Meisel","year":"2023","unstructured":"Meisel A, Annane D, Vu T, Mantegazza R, Katsuno M, Aguzzi R, et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. J Neurol. 2023;270(8):3862\u201375. https:\/\/doi.org\/10.1007\/s00415-023-11699-x.","journal-title":"J Neurol"},{"issue":"4","key":"457_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12185-023-03630-x","volume":"118","author":"JI Nishimura","year":"2023","unstructured":"Nishimura JI, Kawaguchi T, Ito S, Murai H, Shimono A, Matsuda T, et al. Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan. Int J Hematol. 2023;118(4):419\u201331. https:\/\/doi.org\/10.1007\/s12185-023-03630-x.","journal-title":"Int J Hematol"},{"issue":"17 Suppl. 2","key":"457_CR29","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1212\/wnl.0000000000202295","volume":"100","author":"E Greene","year":"2023","unstructured":"Greene E, Cutter G, Muppidi S, Juel V, Rodrigues E, Korideck H, et al. Myasthenia gravis activities of daily living (MG-ADL) response to eculizumab treatment in patients from the generalized myasthenia gravis registry (P1\u20135.020). Neurology. 2023;100(17 Suppl. 2):2071. https:\/\/doi.org\/10.1212\/wnl.0000000000202295.","journal-title":"Neurology"},{"issue":"17 Suppl. 2","key":"457_CR30","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1212\/wnl.0000000000202372","volume":"100","author":"M Pulley","year":"2023","unstructured":"Pulley M, Macwan S, Nowak R, Mozaffar T, Rodrigues E, Korideck H, et al. Change in concomitant therapies for generalized myasthenia gravis in patients receiving eculizumab: a retrospective analysis of registry data (P1-5.002). Neurology. 2023;100(17 Suppl. 2):2183. https:\/\/doi.org\/10.1212\/wnl.0000000000202372.","journal-title":"Neurology"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-024-00457-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-024-00457-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-024-00457-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T16:59:30Z","timestamp":1732640370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-024-00457-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["457"],"URL":"https:\/\/doi.org\/10.1007\/s40801-024-00457-8","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"23 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research funding for this study and funding for medical writing assistance and open-access fees were provided by Alexion, AstraZeneca Rare Disease.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Richard J. Nowak has received research support from Alexion, AstraZeneca Rare Disease, argenx, Genentech, Grifols, Immunovant, Inc., Momenta Pharmaceuticals, the Myasthenia Gravis Foundation of America, the National Institutes of Health (National Institute of Neurological Disorders and Stroke and National Institute of Allergy and Infectious Diseases), Ra Pharmaceuticals (now UCB), and Viela Bio Inc. (now Horizon Therapeutics); and consultancy fees from Alexion, AstraZeneca Rare Disease, argenx, Cour Pharmaceuticals, Grifols, Immunovant, Inc., Momenta Pharmaceuticals, Ra Pharmaceuticals (now UCB), Roivant Sciences, and Viela Bio (now Horizon Therapeutics). Ali A. Habib has served as a medical advisor and speaker on behalf of Alexion and AstraZeneca Rare Disease; he has received research support from Alexion, AstraZeneca Rare Disease, and Cabaletta Bio; and has received research support and honoraria from argenx, UCB, Pfizer, Genentech, Viela Bio, and Regeneron. Andrew J. Klink is a salaried employee of and owns stock in Cardinal Health, which received funding from Alexion, AstraZeneca Rare Disease for work performed on this study. Srikanth Muppidi has served on advisory board meetings for Alexion, AstraZeneca Rare Disease, argenx, Horizon Therapeutics, and Ra Pharmaceuticals (now UCB). Anju Parthan was an employee of Alexion, AstraZeneca Rare Disease, and owned stock in AstraZeneca at the time the study was conducted and analyzed. S. Chloe Sader is an employee of Alexion, AstraZeneca Rare Disease and owns stock in AstraZeneca. Alexandrina Balanean is a salaried employee of Cardinal Health, which received funding from Alexion, AstraZeneca Rare Disease for work performed on this study. Ajeet Gajra was a salaried employee of and owned stock in Cardinal Health, which received funding from Alexion, AstraZeneca Rare Disease for work performed on this study, at the time the study was conducted. James F. Howard Jr has received research support (paid to institution) from Ad Scientiam, Alexion, AstraZeneca Rare Disease, argenx, Cartesian Therapeutics, the Centers for Disease Control and Prevention (Atlanta, GA, USA), the Myasthenia Gravis Foundation of America, the Muscular Dystrophy Association, the National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), PCORI, and UCB Pharma; honoraria from Alexion AstraZeneca Rare Disease, Amgen, argenx, Biohaven Ltd, Biologix Pharma, CheckRare CME, F. Hoffman-LaRoche, Medscape CME, Merck EMD Serono, NMD Pharma, Novartis Pharma, PeerView CME, Physicians\u2019 Education Resource CME, PlatformQ CME, Regeneron Pharmaceuticals, Sanofi US, UCB Pharma, and Zai Lab; and non-financial support from Alexion, AstraZeneca Rare Disease, argenx, Biohaven Ltd, Toleranzia AB, UCB Pharma, and Zai Lab.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was reviewed by the Western Institutional Review Board and determined exempt from requiring ethical approval on the basis that the study collected only secondary data, which were limited and comprised only necessary protected health information (e.g., treatment dates, date of death), and that all data were de-identified and aggregated.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As this study involves anonymized structured data, which according to applicable legal requirements do not contain data subject to privacy laws, obtaining informed consent from patients was not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Alexion, AstraZeneca Rare Disease will consider requests for disclosure of clinical study participant-level data provided that participant privacy is assured through methods such as data de-identification, pseudonymization, or anonymization (as required by applicable law), and if such disclosure was included in the relevant study an informed consent form or similar documentation. Qualified academic investigators may request participant-level clinical data and supporting documents (statistical analysis plan and protocol) pertaining to Alexion-sponsored studies. Further details regarding data availability and instructions for requesting information are available in the Alexion Clinical Trials Disclosure and Transparency Policy at .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Study concept: RJN, AJK, SM, AP, SCS, AG. Study design: RJN, AJK, SM, AP, SCS, AB, AG, JFH Jr. Data acquisition: AAH, JFH Jr. Data analysis: RJN, AJK, AP, SCS, AB, AG. Data interpretation: all authors. Drafting\/revision of the article for content: all authors. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}